Table 2.
Clinical characteristics of people with epilepsy (n = 40).
| Variables | Characteristics |
|---|---|
| Age at onset of epilepsy (years), median (range) | 57.5 (30–86) |
| Female sex, No./total No. (%) | 16/40 (40.0) |
| Epilepsy after NCD onset, No./total No. (%) | 33/40 (82.5) |
| Duration between cognitive decline and onset of epilepsy (years), median (range) | 2.00 (−10, 10) |
| Seizure type, No./total No. (%) | |
| FAS | 2/40 (5.0) |
| FIAS | 13/40 (32.5) |
| FBTCS | 14/40# (35.0) |
| GTCS | 11/40 (27.5) |
| NCS | 11/40 (27.5) |
| ASM regimens, No./total No. (%) | |
| Monotherapy | 30/40 (75) |
| Polytherapy | 8/40 (20) |
| Specific ASMs: | |
| • VPA | 9/40 (22.5) |
| • LEV | 7/40 (17.5) |
| • PHT | 6/40 (15.0) |
| • CBZ | 6/40 (15.0) |
| • LTG | 2/40 (5.0) |
| • LTG+VPA | 3/40 (7.5) |
| • LTG+PTH | 1/40 (2.5) |
| • LEV+VPA | 1/40 (2.5) |
| • CBZ+VPA | 1/40 (2.5) |
| • CBZ+LEV+PTH+ZNS | 1/40 (2.5) |
| • Clobazam+LEV+PTH+VPA | 1/40 (2.5) |
| No ASM | 2/40 (5.0) |
FAS, focal aware seizure; FIAS, focal impaired awareness seizure; NCS, non-convulsive seizure; FBTCS, focal to bilateral tonic-clonic seizure; GTCS, generalized tonic-clonic seizure; VPA, valproate; LEV, levetiracetam; PHT, phenytoin; CBZ, carbamazepine; LTG, lamotrigine; ZNS, Zonisamide; ASM, anti-seizure medication.
#
nine of them had both FIAS and secondary generalization.